Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trialTakehito Shukuya, Nobuyuki Yamamoto, Kōichi Goto et al.|The Lancet Oncology|2015Cited by 86
Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.Takehito Shukuya, Nobuyuki Yamamoto, Takeharu Yamanaka et al.|Journal of Clinical Oncology|2015Cited by 4